Close Noetik Faster: SAB Expansion Fuels AI Biomarker Pitch
Noetik just bolstered its SAB with William Grossman. De-risk their pipeline. Pitch our AI biomarker discovery. Close deals faster. Log outreach in your CRM.
Published on
Do not index
Do not index
🚀 Battle Card: Noetik
Quick trigger:
👤 Decision Maker in the News
- William Grossman, M.D., Ph.D., Scientific Advisory Board Member · 🔗 [LinkedIn](https://www.linkedin.com/company/noetik-inc/)
💡 Why It Matters
- This Noetik sales trigger underscores a move to de-risk clinical programs and secure top translational insight at scale. → Source
🎯 Core Pain Point
- Accelerating therapeutic program progression toward clinic
- Ensuring robust regulatory and translational strategies
💰 What to Pitch
- Primary: AI-powered biomarker discovery platform → Reduce time to target identification; a key Noetik sales trigger benefit
- Expansion: High-throughput spatial data integration → Improve patient stratification and trial success
🗺️ Quick Context
- HQ: San Francisco, CA
- Employees: ≈ 150
- Rev: ≈ $50M
🤼 Competitive Intel
Which other vendors you’ll probably face to win Noetik’s business.
- Recursion — AI-driven drug discovery
- Unique edge: Massive in-house screening library
- Evaluated by R&D for rapid hypothesis testing
- Insitro — ML-based biology platform
- Unique edge: Genotype-phenotype modeling at scale
- Evaluated by Translational Sciences for early indication mapping
- Atomwise — Structure-based AI screening
- Unique edge: Strong track record in small-molecule hits
- Evaluated by Chemistry and Biology leads for lead optimization
- BenevolentAI — Knowledge graph and AI inference
- Unique edge: Integrated scientific graph for target ID
- Evaluated by Translational Medicine for target validation
✅ Do-Now Checklist
Connect with William Grossman on LinkedIn (link above) leveraging this Noetik sales trigger
Draft email + DM highlighting platform de-risking benefits
Log outreach steps in CRM (Day 1, Day 3, Day 7)
Next Step
Get intel like this daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑AI-powered biomarker discovery platform❑
PROOF_METRIC = ❑Reduced target identification time by 30%❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = William
COMPANY = Noetik
DEPT = Scientific Advisory Board
SIZE = ≈ 150
BOTTLENECK = Slow progression toward clinic
EVENT = Expands Scientific Advisory Board
DETAIL = Appointment of William Grossman to SAB
PAIN = Accelerating therapeutic program progression toward the clinic
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251001739674&div=41152219
SIM_CO = Recursion
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 150
REV_EST = ≈ $50M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ 150-person Scientific Advisory Board
William—noticed your Scientific Advisory Board team is ≈ 150.
That’s when Slow progression toward clinic slows growth.
We helped Recursion fix this with AI-powered biomarker discovery platform.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about Appointment of William Grossman to SAB — Accelerating therapeutic program progression toward the clinic.
AI-powered biomarker discovery platform. Reduced target identification time by 30%.
Quick chat?